Current Issues in Molecular Biology (Aug 2022)

Presence of Human Papillomavirus DNA in Malignant Neoplasia and Non-Malignant Breast Disease

  • Erika Maldonado-Rodríguez,
  • Marisa Hernández-Barrales,
  • Adrián Reyes-López,
  • Susana Godina-González,
  • Perla I. Gallegos-Flores,
  • Edgar L. Esparza-Ibarra,
  • Irma E. González-Curiel,
  • Jesús Aguayo-Rojas,
  • Adrián López-Saucedo,
  • Gretel Mendoza-Almanza,
  • Jorge L. Ayala-Luján

DOI
https://doi.org/10.3390/cimb44080250
Journal volume & issue
Vol. 44, no. 8
pp. 3648 – 3665

Abstract

Read online

Breast cancer is the leading cause of cancer death among women worldwide. Multiple extrinsic and intrinsic factors are associated with this disease’s development. Various research groups worldwide have reported the presence of human papillomavirus (HPV) DNA in samples of malignant breast tumors. Although its role in mammary carcinogenesis is not fully understood, it is known that the HPV genome, once inserted into host cells, has oncogenic capabilities. The present study aimed to detect the presence of HPV DNA in 116 breast tissue biopsies and classify them according to their histology. It was found that 50.9% of the breast biopsies analyzed were malignant neoplasms, of which 74.6% were histologically classified as infiltrating ductal carcinoma. In biopsies with non-malignant breast disease, fibroadenoma was the most common benign neoplasm (39.1%). Detection of HPV DNA was performed through nested PCR using the external primer MY09/11 and the internal primer GP5+/6+. A hybridization assay genotyped HPV. HPV DNA was identified in 20.3% (12/59) of malignant neoplasms and 35% non-malignant breast disease (16/46). It was also detected in 27.3% (3/11) of breast tissue biopsies without alteration. However, there are no statistically significant differences between these groups and the existence of HPV DNA (p = 0.2521). Its presence was more frequent in non-malignant alterations than in malignant neoplasias. The most frequent genotypes in the HPV-positive samples were low-risk (LR) HPV-42 followed by high-risk (HR) HPV-31.

Keywords